The David H. Koch Institute for Integrative Cancer Research was announced on October 9, 2007. By combining the faculty of the (now former) MIT Center for Cancer Research (CCR) with an equivalent number of distinguished engineers drawn from various MIT departments, the Koch Institute will continue CCR's tradition of scientific excellence while also seeking to directly promote innovative ways to diagnose, monitor, and treat cancer through advanced technology.
For three decades, CCR has been a mainstay of MIT's – and the nation's – efforts to conquer cancer. Its faculty has included five Nobel Prize winners, and the wealth of fundamental discoveries that have emerged under its aegis have helped shape the face of molecular biology. Under the banner of the Koch Institute, the future promises to hold even more astounding advances.
Though we do not directly provide clinical care for cancer patients, discoveries made by Koch Institute scientists and engineers will make a broad impact on how the disease is detected and managed. Applying our great strengths in science and technology, and working closely with our clinical collaborators, we will be tireless in unraveling the complexities of this disease and bringing new discoveries to patients.
The Koch Institute includes over 40 laboratories and more than 500 researchers located at our headquarters and across the MIT campus. This group includes cancer biologists, genome scientists, chemists, engineers, and computer scientists, all dedicated to bringing the most advanced science and technology to bear in the fight against cancer. In late 2010, we will move into a new state-of-the-art research facility that will be like none other in the world.
The CCR has had a remarkably rich and productive history. However, I believe that our greatest contributions are yet to come. Eliminating cancer will require the integrated application of the best science and technology, and the Koch Institute will be at the vanguard of this new revolution in cancer research.
Tyler Jacks, Ph.D.
Director
Tyler Jacks, Ph.D.
Director, David H. Koch institute for Integrative Cancer Research
